Dr. Daniel J. Deangelo, M.D.,PH.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 251
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 81332
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 251
- Services billed
- 728
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 357 | 147 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 159 | 46 |
| Established patient office or other outpatient visit, 20-29 minutes | 71 | 53 |
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 34 |
| New patient office or other outpatient visit, 60-74 minutes | 38 | 38 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | 12 |
| Hospital discharge day management, more than 30 minutes | 16 | 16 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydroxyurea Other prescribers in Boston, MA | 109 |
| Jakafi (ruxolitinib phosphate) | 103 |
| Imatinib Mesylate | 80 |
| Ayvakit (avapritinib) | 51 |
| Sprycel (dasatinib) | 42 |
| Venclexta (venetoclax) | 27 |
| Prednisone Other prescribers in Boston, MA | 26 |
| Scemblix (asciminib hydrochloride) | 22 |
| Deferasirox | 19 |
| Allopurinol Other prescribers in Boston, MA | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 20 payments worth $37,395 in total to this clinician.
| Autolus Inc | $6,635 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $5,814 |
| Pfizer Inc. | $5,240 |
| Geron Corporation | $3,491 |
| Novartis Pharmaceuticals Corporation | $3,400 |
| Sobi, Inc | $2,775 |
| Servier Pharmaceuticals LLC | $2,720 |
| Syndax Pharmaceuticals, Inc. | $2,408 |
| Consulting Fee | $24,850 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $11,875 |
| Travel and Lodging | $444 |
| Food and Beverage | $226 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Autolus Inc May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,635 |
| AstraZeneca Pharmaceuticals LP Feb 20, 2025 | Consulting Fee | $5,740 |
| Pfizer Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) BOSULIF · METABOLIC DISEASE;ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Novartis Pharmaceuticals Corporation Jun 26, 2025 | Consulting Fee | $3,400 |
| Geron Corporation Dec 18, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $2,925 |
| Sobi, Inc Jun 11, 2025 | Consulting Fee Vonjo · Hematology/Oncology | $2,775 |
| Servier Pharmaceuticals LLC Nov 12, 2025 | Consulting Fee Asparlas · Oncology | $2,720 |
| Syndax Pharmaceuticals, Inc. Aug 7, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,400 |
| Adaptive Biotechnologies Corporation Apr 11, 2025 | Consulting Fee clonoSEQ · Devices | $2,400 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Consulting Fee | $2,240 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Geron Corporation Dec 18, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $2,925 |
| Geron Corporation Dec 18, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to ORLANDO, FL | $93.63 |
| Geron Corporation Dec 9, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to ORLANDO, FL | $350 |
| Servier Pharmaceuticals LLC Nov 12, 2025 | Consulting Fee Asparlas · Oncology | $2,720 |
| Merck Sharp & Dohme LLC Sep 22, 2025 | Consulting Fee | $2,240 |
| Pfizer Inc. Aug 14, 2025 | Compensation for services other than consulting (speaking, faculty) BESPONSA · ONCOLOGY | $1,540 |
| Syndax Pharmaceuticals, Inc. Aug 7, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,400 |
| Novartis Pharmaceuticals Corporation Jun 26, 2025 | Consulting Fee | $3,400 |
| Pfizer Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) BOSULIF · METABOLIC DISEASE;ONCOLOGY · in-kind Company’s descriptionNo payment was made directly to this author. This is a fair market value payment for editorial or medical writing services paid to a 3rd-party vendor to assist with the development of a publication. | $3,700 |
| Sobi, Inc Jun 11, 2025 | Consulting Fee Vonjo · Hematology/Oncology | $2,775 |
| Autolus Inc May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,635 |
| Adaptive Biotechnologies Corporation Apr 11, 2025 | Consulting Fee clonoSEQ · Devices | $2,400 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 1, 2025 | Consulting Fee | $250 |
| AstraZeneca Pharmaceuticals LP Feb 20, 2025 | Consulting Fee | $5,740 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $334,073 in research payments for these studies, mostly to the institutions running them.
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation · Completed · NCT03580655 - Calaspargase pegol in adults with all
Servier Bioinnovation - (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation · Active, not recruiting · NCT03731260 - A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Celgene Corporation · Terminated · NCT02848001 - A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies
Sanofi US Services Inc. - AUTO1-AL1
Autolus Inc - Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
AbbVie Inc. · Active, not recruiting · NCT03386513
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.